



Systematic Review First-Trimester Influenza Infection Increases the Odds of Non-Chromosomal Birth Defects: A Systematic Review and Meta-Analysis

Ákos Mátrai ^{1,2,3}, Brigitta Teutsch ^{2,4}, Alex Váradi ⁴, Péter Hegyi ^{2,4,5}, Boglárka Pethő ^{1,2}, Akari Fujisawa ^{2,6}, Szilárd Váncsa ^{2,4,5}, Balázs Lintner ^{1,2}, Zsolt Melczer ^{1,2} and Nándor Ács ^{1,2,*}

- ¹ Department of Obstetrics and Gynecology, Semmelweis University, 1085 Budapest, Hungary
- ² Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
- ³ Faculty of Health Sciences, University of Pécs, 7621 Pécs, Hungary
- ⁴ Institute for Translational Medicine, Medical School, University of Pécs, 7621 Pécs, Hungary
- ⁵ Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary
- ⁶ Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary
- * Correspondence: acsnandor@gmail.com; Tel.: +36-309520861

Abstract: Viral infections during pregnancy raise several clinical challenges, including birth defects in the offspring. Thus, this systematic review and meta-analysis aims to prove and highlight the risk of birth defects after first-trimester maternal influenza infection. Our systematic search was performed on 21 November 2022. Studies that reported maternal influenza infection in the first trimester and non-chromosomal congenital abnormalities were considered eligible. We used odds ratios (OR) with 95% confidence intervals (CIs) to measure the effect size. Pooled ORs were calculated with a random effects model. Heterogeneity was measured with I² and Cochran's Q tests. We found that first-trimester maternal influenza was associated with increased odds of developing any type of birth defects (OR: 1.5, CI: 1.30–1.70). Moreover, newborns were more than twice as likely to be diagnosed with neural tube defects (OR: 2.48, CI: 1.95–3.14) or cleft lip and palate (OR: 2.48, CI: 1.87–3.28). We also found increased odds of developing congenital heart defects (OR: 1.63, CI: 1.27–2.09). In conclusion, influenza increases the odds of non-chromosomal birth defects in the first trimester. The aim of the present study was to estimate the risk of CAs in the offspring of mothers affected by first-trimester influenza infection.

Keywords: viral infection; pregnancy; congenital malformations

1. Introduction

The recent outbreak of COVID-19 pneumonia, caused by SARS-CoV-2, has highlighted the role of viral infections during pregnancy as well [1,2]. The importance of these infections will probably increase as we face growing risks of pandemics, which may affect the pregnant mother and the fetus [3]. Viral infections during pregnancy raise several clinical challenges, including adverse pregnancy outcomes and birth defects in the offspring [4].

Influenza is an acute infectious disease caused by influenza A, B or C viruses. Most cases occur during epidemic outbreaks, generally between December and March. The latency period between infection and the manifestation of symptoms is about 48 h. Healthy individuals usually recover in 3–7 days; however, influenza may be followed by secondary bacterial infections of the respiratory system [5]. Pregnant women are among the groups that are at increased risk of complications [6].

Influenza may occur in pregnant women. Organogenesis takes place in the first trimester, so any environmental effect that occurs during this period may affect the development of the embryo. However, the role of influenza viruses is debated in the origin of congenital abnormalities (CAs). Some epidemiologic studies have shown a small increase



Citation: Mátrai, Á.; Teutsch, B.; Váradi, A.; Hegyi, P.; Pethő, B.; Fujisawa, A.; Váncsa, S.; Lintner, B.; Melczer, Z.; Ács, N. First-Trimester Influenza Infection Increases the Odds of Non-Chromosomal Birth Defects: A Systematic Review and Meta-Analysis. *Viruses* **2022**, *14*, 2708. https://doi.org/10.3390/v14122708

Academic Editor: Ayato Takada

Received: 11 October 2022 Accepted: 30 November 2022 Published: 2 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). in CAs in general or in some specific CAs (e.g., heart defects, esophageal atresia, anencephaly), while others did not find any increase of CAs after influenza epidemics [7–12]. However, data from these reports are difficult to assess because of lacking serologic proof of the microbial agents, unknown time of infection during pregnancy, restricted numbers of CAs and inadequate controls. One meta-analysis [13] on this topic also highlighted an association between maternal influenza and non-chromosomal birth defects. However, the included studies were not restricted to first-trimester infection It is not clear whether there is a direct link between influenza infection and the development of birth defects or it exerts an indirect teratogenic effect. High fever associated with influenza was assumed to play a causative role in this pathologic process [14].

Our study hypothesized that influenza in the first trimester increases the likelihood of developing congenital abnormalities. Thus, the present study aimed to estimate the risk of CAs in the offspring of mothers affected by influenza during the first trimester of the pregnancy. Worldwide, 3–5% of newborns are affected by a congenital anomaly [14]. These birth defects are to a great extent responsible for infant mortality [15]. The prevention of CAs is considered a public health priority due to their medical and financial consequences. Therefore, finding the role of influenza infection in the development of CAs is also of significant importance.

2. Materials and Methods

The systematic review and meta-analysis is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 Statement (see Supplementary Table S1) [16] and the MOOSE Checklist (see Supplementary Table S2) [17]. We followed the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions [18]. The protocol was prospectively registered in PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD42021283210 (https://www.crd.york.ac.uk/prospero, accessed on 19 October 2021). There was no protocol deviation.

2.1. Systematic Search

The systematic search was performed in three major medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL) and Embase on 20 October 2021, and we reran our search on 21 November 2022. The search key contained the following main components: influenza, pregnancy, birth defect or congenital anomalies. The detailed queries are shown in the Supplementary Material. There were no filters or other restrictions used during the search.

2.2. Selection and Eligibility Criteria

We used EndNote 20 (Clarivate Analytics, Philadelphia, PA, USA) to select the retrieved articles. After removing duplications, two independent authors screened the library separately by title and abstract, then by full text (\hat{A} .M., A.F.). We calculated Cohen's kappa coefficient (κ) after each selection process to measure interrater reliability [19]. Disagreements were resolved after each step by a third author (B.T.).

We used the population-exposure-outcome (PEO) framework to structure our research question. Case-control studies and cohort analyses, including pregnant women (P), who were investigated for influenza infection (E) during the first trimester of pregnancy, were found eligible. The outcomes of interest were all types of non-chromosomal birth defects (O).

The exclusion criteria concerned conference abstracts, articles reporting on common cold or fever instead of influenza, and influenza before or after the first trimester. To identify all relevant articles on the topic, the reference list of eligible full texts, and studies that cited the key articles were also checked. If the articles were not written in English, we sought the help of a translator. We contacted the authors if there was no available text or data from an article. When the study population was overlapping for an outcome, we included the study with a larger sample size.

2.3. Data Extraction

Two authors independently (A.M., A.F.) extracted the data. We created a standardized data collection Excel sheet (Office 365, Microsoft, Redmond, WA, USA), which included first author, year of publication, title of the study, digital object identifier (DOI) number, study design, study type, study period, country, number of the participant centers, demographic characteristics of the included patients, number of participants, population characteristics of the study, data about the exposure (definition, time), raw data regarding the outcomes and unadjusted and adjusted results separately. A third author (B.T.) resolved the disagreements between the two authors.

2.4. Data Synthesis and Analysis

Qualitative data synthesis was done in the R programming language (R Core Team, 2012, Vienna, Austria, R version 4.2) using the meta v5.5.0 [20] and dmetar v0.0.9000 packages. A meta-analysis was performed if there were a minimum of three studies for one outcome. Where pooling effect sizes could not be carried out, we only visualized results on forest plots.

When possible, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from 2 by 2 tables raw data or from crude ORs for the specific outcomes. Where possible, pooled adjusted ORs (AORs) were also estimated. A *p*-value less than 0.05 was considered statistically significant. Since we anticipated considerable between-study heterogeneity, a t random-effects model was applied in case of raw data using the Mantel-Haenszel [21,22] method by metabin function from meta package, and we applied the Paule-Mandel method to estimate the between-study variance [23]. Other cases we used already calculated crude or adjusted ORs and their standard errors for pooling with restricted maximum likelihood methods [24] with the help of metagen function. Heterogeneity was tested with I² and Cochran Q tests; *p* < 0.1 indicated significant heterogeneity [25].

Following the recommendations of IntHout et al. (2016), where applicable, we also reported the prediction intervals (i.e., the expected range of effects of future studies) of the pooled estimates.

There were less than 10 studies for each outcome; therefore, a publication bias assessment could not be performed.

2.5. Risk of Bias Assessment and Quality of Evidence

The risk of bias assessment was performed by two review authors (Å.M., B.P.) independently using the Quality in Prognosis Studies (QUIPS) tool [26]. Disagreements were resolved by a third review author (B.T.). We visualized our results in figures with the Riskof-bias VISualization (robvis) tool [27]. The overall assessment was considered low-risk if only low-risk bias domains existed. If one domain was at high risk or three out of six domains were at moderate risk, the overall result was reported as having a high risk of bias. The quality evaluation of the evidence was performed following the recommendations of the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) workgroup. We prepared the summary of findings tables with the GRADEPro Guideline Development Tool [28].

3. Results

3.1. Search and Selection

The systematic search yielded 10,450 records. After the duplication removal process, 6229 records remained. All records were checked by title and abstract, and 195 by full text. After overlapping populations were excluded, 14 articles [8,29–40] were included in the qualitative and quantitative synthesis. The selection process and Cohen's kappas are shown in Figure 1.



Figure 1. Flowchart of the systematic search and selection.

3.2. Basic Characteristics of Included Studies

Baseline characteristics of the enrolled analyses are shown in Table 1. We included 13 case-control studies [8,29–32,34–41], and one retrospective cohort analysis [33]. The overall study period of the articles is placed between 1960 and 2020. The largest database included in the meta-analysis was the Hungarian Case-Control Surveillance of Congenital Abnormalities [29,34]. The diagnosis of influenza infection was in most cases based on the symptoms of the disease by using retrospective questionnaires. There was only one study in which the disease was confirmed by a polymerase chain reaction (PCR) test [33]. In most of the studies, the age of the mothers was between 20–34 years. The summary table of the outcomes of the included studies was shown also in the Supplementary Material (Table S3).

Author, Year	Study Type	Country	Number of the Participant Centers	Examination Period	Number of Patients (Cases-Controls)	Age Groups	Diagnosis of Influenza	Congenital Malformations	Adjusted for
L. Ács et al., 2020 [29]	Case-control	Hungary	No data	1980–1996, 2007–2009	1947 (751–1196)	<23; 23–33; >33	Prospective, medically recorded data; retrospective questionnaire, supplementary data collection	Cleft palate	
Ács et al., 2005 [30]	Case-control	Hungary	No data	1980–1996	3166 (1328–1838)	≤24; 25–29; >30	Prospective, medically recorded data; retrospective questionnaire, supplementary data collection	Neural tube defects; Cleft lip/palate; Cleft palate; Esophageal atresia; Pyloric stenosis; Intestinal atresia/stenosis; Rectal/anal stresia/stenosis; Renal a/dysgenesia; Obstructive urinary Cas; Hypospadiasis; Undescended testis; Exomphalos/gastroschisis; Congenital hydrocephaly, Ear CAs, Cardiovascular CAs, Clubfoot, Limb reduction defects, Poly/syndactilia, Diaphragmatic CAs, Other Isolated CAs, Multiple CAs	maternal employment status and use of antipyretic drugs
Aro et al., 1983 [<mark>31</mark>]	Case-control	Finland	No data	1964–1977	906 (453–453)	No data	Personal visits, questionnaire	limb reduction defects	
Botto et al., 2001 [32]	Case-control	USA	No data	1968–1980	3934 (905–3029)	11–19, 20–24, 25–29, 30–34, >35	Telephone interview	Congenital heart defects, Transposition of great arteries, Tetralogy of Fallot, Atrioventricular septal defect, Ebstein anomaly, Anomalous pulmonary venous return, All right obstructive defects, Tricuspid atresia, All left obstructive defects, Hypoplastic left heart, Aortic stenosis, Aortic coarctation, Ventricular septal defect, Atrial septal defect	maternal race, education, multivitamin use, smoking, alcohol use, chronic illnesses, and period of birth of the child
Busby et al., 2005 [33]		England	No data	1987–1994	275		General practitioner data, laboratory data	Anophtalmia, Micophtalmia	

Table 1. Basic characteristics of included studies.

Author, Year	Study Type	Country	Number of the Participant Centers	Examination Period	Number of Patients (Cases-Controls)	Age Groups	Diagnosis of Influenza	Congenital Malformations	Adjusted for
Czeizel et al., 2008 [34]	Case-control	Hungary	No data	1980–1996	3754 (1349–2405)	No data	Prospective, medically recorded data; retrospective questionnaire, supplementray data collection	Neural-tube defects, Anencephalus+-spina bifida, Spina bifida aperta/cystica, Encephalocele, occipital, Microcephaly, primary, Congenital hydrocephalus, CAs of eye, Anophthalmia- microphthalmia, Primary congenital glaucoma, Congenital cataract, Ocular coloboma, CAs of ear, Auditory canal+ear Cas, An/microtia, Others, unspecified, Cardiovascular CAs, Transposition of great vessels, Ventricular septal defect, Atrial septal defect, type II, Hypoplastic left heart, Patent ductus arteriosus, CAs of aorta, CAs of pulmonary valve, Others or unspecified, Brachial cyst, cleft, fistula, preauricular sinus, CAs of respiratory system, Cleft palate, Robin sequence, Cleft lip+-cleft palate, Cleft lip, Cleft lip with palate, Esophageal atresia/stenosis with or without tracheoesophageal fistula, Cong hypertrophic pyloric stenosis, Atresia/stenosis of small intestine, Atresia/stenosis of rectum/anal canal, Other CAs of digestive system, Hirschprung's disease, Other CAs of intestine, Other CAs of digestive system, Undescended testis (diagnosed after 3rd postnatal month), Hypospadias (without coronal type), Other CAs of genital organs, Renal a/dysgenesis,	

Table 1. Cont.

Number of the Number of Diagnosis of Influenza Examination Author, Year Study Type Participant Age Groups **Congenital Malformations** Adjusted for Country Patients Period (Cases-Controls) Centers Obstructive CAs of urinary tract, Cystic kidney (diseases), Obstructive CAs of renal pelvis and ureter (hydronephrosis, constricture of ureteropelvic junction and ureterovesical orifice), Other CAs of urinary Prospective, tract, Other CAs of kidney, medically recorded Other CAs of bladder and 3754 (1349–2405) data; retrospective Czeizel et al., urethrea, Clubfoot, Case-control Hungary No data 1980-1996 No data 2008 [34] questionnaire, Poly/syndactyly, Polydactyly, supplementray Syndactyly (without minor), data collection Limb deficiencies, Other CAs of limbs, CAs of diaphragm, CAs of abdominal wall (exomphalos and gastroschisis are not differentiated), Multiple CAs (major gene mutations and chromosomal aberrations are excluded) Retrospective Dymanus et al., observational USA No data 2004-2013 58,270 No data Cleft lip 2019 [41] population study Anencephalia, Spina bifida, Granroth 1420 Congenital hydrocephaly, 1965-1973 No data Questionnaire Case-control Finland No data 1978 [35] (710 - 710)Microcephaly, Hydrancephaly, Polydactylia maternal age, All congenital heart defects, maternal Septal defects, Conotruncal education, defects, Right-sided maternal BMI, Li et al., 710 <20, 20-24, 25-29, Case-control China No data 2010-2011 Questionnaire obstructive defects, Left-sided supplementation, 2014 [8] (294 - 416)30–34, ≥35 obstructive defects, and history of Anomalous pulmonary venous pregnancy with return, Other isolated CAs any defect

		Table 1. Cont							
Author, Year	Study Type	Country	Number of the Participant Centers	Examination Period	Number of Patients (Cases-Controls)	Age Groups	Diagnosis of Influenza	Congenital Malformations	Adjusted for
Lynberg et al., 1994 [36]	Case-control	USA	No data	1968–1980	329 (31–298)	No data	Questionnaire	Anencephalia, Spina bifida, Encephalocele	maternal age, education, smoking, alcohol consumption, and periconceptional multivitamin use
Ou et al., 2015 [37]	Case-control	China	39	2004–2013	8068 (4034–4034)	<30, 30–34, 35–40, >40	Questionnaire	Cardiovascular CAs, Ventricular septal defect, Atrial septal defect, Pulmonary stenosis, Dextro-transposition of great arteries, Tetralogy of Fallot	
Park et al., 1993 [38]	Case-control	USA	No data	1968–1980	1490 (304–1186)	11–19, 20–34, >35	Questionnaire	Anencephalia, Spina bifida	
Saxen et al., 1975 [39]	Case-control	Finland	No data	1972–1973	388 (194–194)	<u>≥</u> 30 (23%)	Maternity records, interview records, death certificates	Cleft lip and palate	
Saxen et al., 1975 [40]	Case-control	Finland	No data	1967–1971	1198 (599–599)	≥30 (30.7%)	Maternity records, interview records, death certificates	Cleft lip and palate	

3.3. Non-Chromosomal Congenital Malformations

Only one article reported a total number of non-chromosomal congenital malformations [30]. On the basis of their results, first-trimester maternal influenza was associated with 1.5 times increased odds (CI: 1.30–1.70) of developing all types of non-chromosomal birth defects.

3.4. Influenza Increases the Odds of Neural Tube Defects

Four eligible articles [34–36,38] reported on neural tube defects (NTDs). Our results highlighted that first-trimester maternal influenza infection increased the odds of developing NTDs (OR: 2.48, CI: 1.95-3.14; $I^2 = 0\%$, CI: 0-85%; Figure 2).

Study	OR	95%-CI	Weight	Odds Ra	tio
Czeizel et al. 2008	2.00	[1.37; 2.93]	38.9%	-	-
Granroth 1978	2.58	[1.50; 4.44]	19.1%		
Lynberg et al. 1994	2.87	[1.87; 4.40]	30.9%		
Park et al. 1993	3.26	[1.59; 6.67]	11.0%		
Random effects model	2.48	[1.95; 3.14]	100.0%		\diamond
Prediction interval		[1.47; 4.17]			
Heterogeneity: $I^2 = 0\%$ [0%	; 85%],	$\tau^2 = 0, p = 0.52$	4		
Test for overall effect: $z = 7$.	47 (p <	0.001)		0.2 0.5 1	2 5

Figure 2. The odds of developing neural tube defects after influenza infection in the first trimester [34-36,38].

Pooled results from three articles [34–36] showed that influenza was associated with more than two times increased odds for the development of spina bifida (OR: 2.22, CI: 1.58-3.12; I² = 0%, CI: 0-90%; Figure 3).



Figure 3. The odds of developing spina bifida after influenza infection in the first trimester [34–36].

Two studies provided data for the assessment of encephalocele. Czeizel et al. [34] reported an almost twofold increase (OR: 1.70 CI: 0.69–4.16), whereas Lynberg et al. [36] reported an almost fourfold increase (OR: 3.94 CI: 1.34–11.58) in the development of this outcome. Granroth et al. [35] and Czeizel et al. [34] reported data about the development of microcephaly and hydrocephalus after first-trimester maternal influenza. They found a twofold increase in odds for microcephaly (Granroth et al. [35]: OR: 2.05 CI: 0.18–23.55; Czeizel et al. [34]: OR: 2.30 CI: 0.39–13.66) and a two-and-a-half-fold increase in odds

for hydrocephalus (Granroth et al. [35]: OR: 2.61 CI: 0.99–6.86; Czeizel et al. [34]: OR: 2.30 CI: 1.12–4.70). When assessing spina bifida of the lower and upper part of the spine, Park et al. [38] reported an almost fourfold increase (OR: 3.73 CI: 1.72–8.09) and a four-and-a-half-fold increase (OR: 4.57 CI: 1.81–11.52) after first-trimester maternal influenza infection, respectively. These results are visualized in the Supplementary Material (Figure S1).

3.5. Oral Clefts

The association between first-trimester maternal influenza infection and cleft lip and palate was reported in four articles [34,39–41]. Overall results showed an almost 2.5-fold increase in the development of cleft lip and palate (OR: 2.48, CI: 1.87–3.28; $I^2 = 19\%$, CI: 0–88%; Figure 4). Also, Czeizel et al. found an association between the assessed risk factor and cleft lip (OR: 2.40, CI: 1.42–4.06). Moreover, L. Ács et al. found an even stronger association between the assessed exposure and cleft palate (OR: 2.95, CI: 1.75–4.95).



Lower with influenza Higher with influenza

Figure 4. The odds of developing oral clefts after influenza infection in the first trimester [34,39–41].

3.6. Congenital Heart Defects

Several studies [33,36,37,42] provided data for congenital heart defects. Li et al. [8] found 1.62 times higher odds (CI: 1.17–2.24), and Czeizel et al. [34] reported 1.90 times higher odds (CI: 1.50–2.40) for developing all types of congenital heart defects. Several studies also found a significant association between influenza and aortic, conotruncal, septal and ventricular septal defects. Odds ratios for the subtypes of congenital heart defects are presented in Table 2.

Study	Congenital Heart Defects	Odds Ratios
Li et al., 2014 [8]	Anomalous pulmonary venous return	0.80 (CI: 0.36-1.79)
Czeizel et al., 2008 [34]	Atrial septal defect	1.70 (CI: 0.42-6.96)
Czeizel et al., 2008 [34]	CAs of the aorta	4.60 (CI: 1.41-15.01)
Czeizel et al., 2008 [34]	CAs of the pulmonary valve	1.20 (CI: 0.38-3.75)
Li et al., 2014 [8]	Conotruncal defects	1.71 (CI: 1.13-2.58)
Czeizel et al., 2008 [34]	Hypoplastic left heart	1.60 (CI: 0.31-8.26)
Li et al., 2014 [8]	Left-sided obstructive heart defects	1.50 (CI: 0.84-2.68)
Czeizel et al., 2008 [34]	Patent ductus arteriosus	0.80 (CI: 0.08-7.55)
Li et al., 2014 [8]	Right-sided obstructive heart defects	1.40 (CI: 0.80-2.45)
Li et al., 2014 [8]	Septal defects	1.92 (CI: 1.31-2.82)
Czeizel et al., 2008 [34]	Transposition of great vessels	2.90 (CI: 0.90-9.32)
Czeizel et al., 2008 [34]	Ventricular septal defect	2.70 (CI: 1.59-4.58)

Table 2. Unadjusted odds ratios for developing specific types of congenital heart defects after influenza infection in the first trimester.

Three studies [8,32,37] reported adjusted odds ratios (AORs). The pooled results showed a more than 1.5 times increase in the odds of developing congenital heart defects (AOR: 1.63, CI: 1.27–2.09; $I^2 = 0\%$, CI: 0–90%; Figure 5).



Lower with influenza Higher with influenza

Figure 5. Adjusted odds ratio of developing congenital heart defects after influenza infection in the first trimester [8,32,37].

We also found a positive association between influenza and specific types of congenital heart defects when the analysis was performed with multiple logistic regression. The results of the studies showed an almost fourfold increase in the development of aortic coarctation, an almost threefold increase in the development of left-sided obstructive heart defects and a two-and-a-half-fold increase in the development of right-sided obstructive heart defects. The findings of the studies showed an almost threefold increase in the development of atrial septal defects, a twofold increase in the development of ventricular septal defects, more than one-and-a-half-fold increase in the development of conotruncal defects. These results are shown in Table 3.

Botto et al., 2001 [32]Anomalous pulmonary venous return2.20 (CI: 0.29-16.51)Botto et al., 2001 [32]Aortic coarctation3.80 (CI: 1.62-8.91)Botto et al., 2001 [32]Aortic stenosis4.00 (CI: 0.90-17.84)Botto et al., 2001 [32]Atrial septal defect1.00 (CI: 0.12-8.60)Botto et al., 2001 [32]Ebstein anomaly3.00 (CI: 0.39-23.19)Botto et al., 2001 [32]Hypoplastic left heart1.60 (CI: 0.39-6.55)Botto et al., 2001 [32]Left-sided obstructive heart defects2.90 (CI: 1.49-5.65)Multiple
Botto et al., 2001 [32] Aortic coarctation 3.80 (CI: 1.62-8.91) Botto et al., 2001 [32] Aortic stenosis 4.00 (CI: 0.90-17.84) Botto et al., 2001 [32] Atrial septal defect 1.00 (CI: 0.12-8.60) Botto et al., 2001 [32] Ebstein anomaly 3.00 (CI: 0.39-23.19) Botto et al., 2001 [32] Hypoplastic left heart 1.60 (CI: 0.39-6.55) Botto et al., 2001 [32] Left-sided obstructive heart defects 2.90 (CI: 1.49-5.65) Multiple
Botto et al., 2001 [32]Aortic stenosis4.00 (CI: 0.90-17.84)Botto et al., 2001 [32]Atrial septal defect1.00 (CI: 0.12-8.60)Botto et al., 2001 [32]Ebstein anomaly3.00 (CI: 0.39-23.19)Botto et al., 2001 [32]Hypoplastic left heart1.60 (CI: 0.39-6.55)Botto et al., 2001 [32]Left-sided obstructive heart defects2.90 (CI: 1.49-5.65)Multiple
Botto et al., 2001 [32]Atrial septal defect1.00 (CI: 0.12-8.60)Botto et al., 2001 [32]Ebstein anomaly3.00 (CI: 0.39-23.19)Botto et al., 2001 [32]Hypoplastic left heart1.60 (CI: 0.39-6.55)Botto et al., 2001 [32]Left-sided obstructive heart defects2.90 (CI: 1.49-5.65)Botto et al., 2001 [32]Left-sided obstructive heart defectsMultiple
Botto et al., 2001 [32]Ebstein anomaly3.00 (CI: 0.39-23.19)Botto et al., 2001 [32]Hypoplastic left heart1.60 (CI: 0.39-6.55)Botto et al., 2001 [32]Left-sided obstructive heart defects2.90 (CI: 1.49-5.65)Multiple
Botto et al., 2001 [32]Hypoplastic left heart1.60 (CI: 0.39-6.55)maternal race, education, multivitamin use, smoking, alcohol use, chronic illnesses,Multiple
Botto et al., 2001 [32] Left-sided obstructive heart defects 2.90 (CI: 1.49–5.65) Multiple Multivitamin use, smoking, alcohol use, chronic illnesses, Multiple
Botto et al., 2001 [32]Right-sided obstructive heart defects2.50 (CI: 1.14-5.49)and period of birth of the child
Botto et al., 2001 [32] Septal defects 2.00 (CI: 0.38-14.28)
Botto et al., 2001 [32] Tetralogy of Fallot 0.50 (CI: 0.08-3.00)
Botto et al., 2001 [32] Transposition of great vessels 2.10 (CI: 0.80–5.51)
Botto et al., 2001 [32] Tricuspid atresia 7.90 (CI: 0.80-78.47)
Botto et al., 2001 [32] Ventricular septal defect 2.00 (CI: 1.11–3.62)
Li et al., 2014 [8] Anomalous pulmonary venous return 0.68 (CI: 0.28–1.65)
Li et al., 2014 [8] Conotruncal defects 1.60 (CI: 1.01–2.52) maternal age, maternal
Li et al., 2014 [8] Left-sided obstructive heart defects 1.55 (CI: 0.82–2.93) education, maternal body mass index (BMI), supplementation, Multivariate and history of premancy with
Li et al., 2014 [8] Septal defects 2.12 (CI: 1.38–3.26) any defect
Li et al., 2014 [8] Right-sided obstructive heart defects 1.26 (CI: 0.68–2.34)
Ou et al., 2015 [37] Atrial septal defect 2.71 (CI: 1.17–6.33) maternal age, maternal pregnancy
Ou et al., 2015 [37] Pulmonary stenosis 0.62 (CI: 0.07-5.58) history, maternal
Ou et al., 2015 [37]Transposition of great vessels1.15 (CI: 0.07-19.22)environmental risk exposures, maternal perinatal diseases, and medication use in theMultivariate
Ou et al., 2015 [37] Ventricular septal defect 1.19 (CI: 0.71–1.99) first trimester

Table 3. Detailed odds ratios for developing specific congenital heart defects after influenza in the first trimester.

3.7. Other Types of Birth Defects

In our systematic review, several studies reported data on the association of influenza and other specific types of birth defects. Aro et al. [31] and Czeizel et al. [34] found a positive association between first-trimester maternal influenza infection and limb reduction defects (OR: 1.98, CI: 1.13–3.46; OR: 2.30, CI: 1.30–4.08, respectively). These findings are shown in the Supplementary Material (Figure S2).

We also found an association between maternal influenza and eye anomalies. Busby et al. [33] reported 1.26-fold odds (OR: 1.26, CI: 1.02–1.56), whereas Czeizel et al. [34] reported 1.30-fold odds (OR: 1.30, CI: 0.47–3.58) for the development of congenital malformations of the eyes. These findings are also shown in the Supplementary Material (Figure S3).

Several additional congenital malformations were found to be associated with first-trimester influenza infection. Details of the results can be found in Table S4.

3.8. Risk of Bias Assessment and Level of Evidence

The evaluation was based on six criteria. Every domain was scored as carrying low, moderate or high risk of bias for all the included outcomes. The results of the risk of bias assessment are presented in the Supplementary Material (Figures S4–S14). As the prognostic factor measurement was not carried out with PCR and the chances of recall bias were high, the overall risk of bias was high in most of the included studies. Also, the quality of evidence was very low for most of the results (Table S5).

4. Discussion

The importance of viral infections will increase as we face growing risks of pandemics, which may affect the pregnant mother and the fetus [42]. Viral infections during pregnancy raise several clinical challenges, including adverse pregnancy outcomes and birth defects in the offspring [3]. During embryogenesis, the development of different organs and organ systems occurs one after the other and parallel to others. Almost every organ system develops in the first 12 weeks of pregnancy, so any effect on the embryo during this period may significantly influence the development of birth defects.

This systematic review and meta-analysis evaluated the effects of influenza infection in the first trimester of pregnancy on the development of non-chromosomal birth defects.

We know from a previous study by Acs et al. [30] that the odds of developing all types of non-chromosomal birth defects are 1.5 times higher if influenza is present in the first trimester (OR: 1.40; CI: 1.30-1.60). Oster et al. [43] got the same association (OR: 1.11; CI: 0.91-1.35) between influenza and birth defects in the USA. On the basis of the results of this meta-analysis, we could also confirm the association between first-trimester maternal influenza and the development of non-chromosomal congenital malformations. Moreover, our results showed increased odds of developing three major types of CAs, namely congenital heart defects, neural tube defects and oral clefts after influenza infection in the first three months of pregnancy.

Neural tube defects are congenital brain, spine, or spinal cord abnormalities. Many studies [44–46] have investigated the pathogenesis of NTDs. Among the epidemiology and risk factors chromosomal anomalies (trisomy 13, 18 and triploidy) represent less than 10% of all NTDs [47]. Maternal diabetes, obesity, maternal hyperthermia (use of sauna, hot water tube, and fever), medication (valproate) and low folate intake were also considered as risk factors for developing NTDs [48]. The quantitative and qualitative synthesis of our findings in the present study confirmed the association between influenza and neural tube defects [34–36]. Their significance is outstanding as they are amongst the most common causes of genetic abortions. Most importantly, we can decrease the development of these congenital malformations with folic acid supplementation [49].

Our findings also confirmed the association between the development of cleft lip and palate and first-trimester maternal influenza. Orofacial clefts are common birth defects, estimated at 1.5 per 1000 live births worldwide [50]. Newborns with these anomalies have feeding difficulties and often develop conductive hearing loss and speech problems [51]. Environmental agents and genetic factors were also linked with the development of these birth defects. Moreover, orofacial clefts were also associated with teratogenetic agents, such as alcohol or anticonvulsant drugs. However, folic acid deficiency can also increase the chances for these birth defects [52,53]. In a population-based case-control study, L. Ács et al. [29] confirmed that influenza is a risk factor for developing cleft palate like other lifestyle factors (gender, birthweight and smoking) or illnesses. Waller et al. [7] examined common cold/flu during the periconceptional period, and they assessed that the odds of developing a cleft lip was 1.23 (CI: 1.05-1.45).

Congenital heart defects are among the most prevalent birth defects, and they remain an important causative factor of neonatal and infant deaths. The risk of these birth defects was associated with low maternal education, pregestational diabetes, self-reported maternal clotting disorders, prescriptions for anticlotting medication [43] and maternal influenza infection [43,54]. Our results could prove the association between influenza infection and congenital heart disease [8,34].

Organogenesis takes place during the first 12–13 weeks of pregnancy. This time-frame is the so called critical period for the development of birth defects. Therefore, our metaanalysis focused only on the first three months of pregnancy. We identified several studies, which analyzed the periconceptional period (i.e., three to one months before pregnancy and the first trimester) [8,44,55]. These results do not differ significantly from the results we have obtained. Further studies have shown that if fever during an influenza infection was relieved effectively with antipyretic drugs, malformations are less likely to develop [30]. Several studies have also shown that taking folic acid and maternal vitamins during the first trimester of pregnancy can reduce the odds of developing birth defects [30,56].

4.1. Strengths and Limitation

To our knowledge, this is the first meta-analysis that investigated the association between maternal influenza and all types of non-chromosomal abnormalities during the first trimester. We followed our protocol, which was registered previously. Our investigation covered a long study period with a large number of cases. The articles were from all over the world, giving a comprehensive picture of the disease and its effects.

In consideration of the limitations of this analysis, most studies defined the diagnosis of influenza based on the symptoms (headache, fever, running nose and muscle pain) and reported data that were retrospective and self-reported. Thus, the risk of bias was high because of the prognostic factor measurement. Most of the studies included were case-control investigations, where a high percentage of recall bias is to be expected. We could include only one study in which a serological test identified the disease. Because of the rigorous methodology and timing, there were few cases for one outcome.

4.2. Implications for Practice and Research

Translating scientific results into everyday practice has crucial importance [56]; therefore, we should make efforts to prevent influenza during pregnancy and highlight the importance of vaccination against flu and antipyretic therapy. We suggest that if influenza is presented in the critical pregnancy period, great emphasis should be placed on prenatal screening. Additional prospective observational studies should be performed with the use PCR to confirm first-trimester influenza infection.

5. Conclusions

In conclusion, our systematic review found that influenza in the first trimester is associated with non-chromosomal birth defects, primarily congenital heart defects, neural tube defects and oral clefts. Therefore, influenza prevention by vaccination before or during pregnancy is highly recommended. Moreover, if influenza has already manifested itself, proper antipyretic treatment should be started.

Supplementary Materials: The following supporting information can be downloaded at: https://www. mdpi.com/article/10.3390/v14122708/s1, Figure S1: Forest plot representing that the odds for developing specific types of neural tube defects was increased after influenza in the first trimester. Figure S2. Forest plot representing that the adjusted odds for developing limb reduction defects was increased after influenza in the first trimester. Figure S3. Forest plot representing that the adjusted odds for developing eye anomalies was increased after influenza in the first trimester. Figure S4. Risk of bias assessment at study and at domain level for all neural tube defects. Figure S5. Risk of bias assessment at study and at domain level for spina bifida. Figure S7. Risk of bias assessment at study and at domain level for cleft lip and palate. Figure S8. Risk of bias assessment at study and at domain level for cleft lip, palate. Figure S9. Risk of bias assessment at study and at domain level for cleft lip, palate. Figure S9. Risk of bias assessment at study and at domain level for cleft lip, palate. Figure S9. Risk of bias assessment at study and at domain level for congenital heart disease (adjusted). Figure S11. Risk of bias assessment at study and at domain level for congenital heart disease in the systematic review (unadjusted). Figure S12.

15 of 17

Risk of bias assessment at study and at domain level for congenital heart disease (unadjusted). Figure S13. Risk of bias assessment at study and at domain level for eye anomalies. Figure S14. Risk of bias assessment at study and at domain level for limb reduction. Figure S15. Search key of the systematic search. Table S1. PRISMA 2020 checklist. Table S2. MOOSE Checklist for Meta-analyses of Observational Studies. Table S3. Table of included studies with outcomes. Table S4. The odds ratios for developing specific types of congenital malformations after first trimester. Table S5. Quality of evidence.

Author Contributions: Á.M.: conceptualization, project administration, writing—original draft; B.T.: project administration, conceptualization, methodology, writing—review and editing; A.V.: formal analysis; visualization; P.H.: project administration, methodology, writing—review and editing; B.P. data curation, review, editing; A.F.: data curation; conceptualization, writing—review and editing; S.V.: conceptualization, writing—review and editing; B.L.: conceptualization, writing—review and editing; Z.M.: conceptualization, writing—review and editing; N.Á.: conceptualization; supervision; writing—original draft. All authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct, or interpretation of our study.

Data Availability Statement: The datasets used in this study can be found in the full-text articles included in the systematic review and meta-analysis.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Qiao, J. What are the risks of COVID-19 infection in pregnant women? *Lancet* 2020, 395, 760–762. [CrossRef]
- Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q.; et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* 2020, 395, 809–815. [CrossRef] [PubMed]
- 3. Silasi, M.; Cardenas, I.; Kwon, J.Y.; Racicot, K.; Aldo, P.; Mor, G. Viral infections during pregnancy. *Am. J. Reprod. Immunol.* **2015**, 73, 199–213. [CrossRef] [PubMed]
- 4. Racicot, K.; Mor, G. Risks associated with viral infections during pregnancy. J. Clin. Investig. 2017, 127, 1591–1599. [CrossRef] [PubMed]
- Pleschka, S. Overview of influenza viruses. In *Current Topics in Microbiology and Immunology*; Springer: Berlin/Heidelberg, Germany, 2013; Volume 370, pp. 1–20. [CrossRef]
- 6. Ghebrehewet, S.; MacPherson, P.; Ho, A. Influenza. BMJ 2016, 355, i6258. [CrossRef]
- Waller, D.K.; Hashmi, S.S.; Hoyt, A.T.; Duong, H.T.; Tinker, S.C.; Gallaway, M.S.; Olney, R.S.; Finnell, R.H.; Hecht, J.T.; Canfield, M.A. Maternal report of fever from cold or flu during early pregnancy and the risk for noncardiac birth defects, National Birth Defects Prevention Study, 1997–2011. *Birth Defects Res.* 2018, *110*, 342–351. [CrossRef]
- 8. Li, M.; Liu, Z.; Lin, Y.; Chen, X.; Li, S.; You, F.; Deng, Y.; Li, N.; Wang, Y.; Zhang, Y.; et al. Maternal influenza-like illness, medication use during pregnancy and risk of congenital heart defects in offspring. *J. Matern. Fetal. Neonatal. Med.* 2014, 27, 807–811. [CrossRef]
- Coffey, V.P.; Jessop, W.J. Maternal influenza and congenital deformities: A prospective study. *Lancet* 1959, 2, 935–938. [CrossRef]
 Campbell, W.A. Influenza in early pregnancy; effects on the foetus. *Lancet* 1953, 1, 173–174. [CrossRef]
- Leck, I. Incidence of malformations following influenza epidemics. *Br. J. Prev. Soc. Med.* **1963**, *17*, 70–80. [CrossRef]
- Doll, R.; Hill, A.B.; Sakula, J. Asian influenza in pregnancy and congenital defects. *Br. J. Prev. Soc. Med.* 1960, 14, 167–172. [CrossRef]
- 13. Luteijn, J.M.; Brown, M.J.; Dolk, H. Influenza and congenital anomalies: A systematic review and meta-analysis. *Hum. Reprod.* **2014**, *29*, 809–823. [CrossRef]
- Mai, C.T.; Isenburg, J.L.; Canfield, M.A.; Meyer, R.E.; Correa, A.; Alverson, C.J.; Lupo, P.J.; Riehle-Colarusso, T.; Cho, S.J.; Aggarwal, D.; et al. National population-based estimates for major birth defects, 2010–2014. *Birth Defects Res.* 2019, 111, 1420–1435. [CrossRef]
- 15. Canfield, M.A.; Honein, M.A.; Yuskiv, N.; Xing, J.; Mai, C.T.; Collins, J.S.; Devine, O.; Petrini, J.; Ramadhani, T.A.; Hobbs, C.A.; et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999–2001. *Birth Defects Res. Part A Clin. Mol. Teratol.* **2006**, *76*, 747–756. [CrossRef]

- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021, 372, n71. [CrossRef]
- Brooke, B.S.; Schwartz, T.A.; Pawlik, T.M. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. *JAMA Surg.* 2021, 156, 787–788. [CrossRef]
- 18. Chandler, J.; Hopewell, S. Cochrane methods–twenty years experience in developing systematic review methods. *Syst. Rev.* 2013, 2, 76. [CrossRef]
- 19. McHugh, M.L. Interrater reliability: The kappa statistic. Biochem. Med. 2012, 22, 276–282. [CrossRef]
- 20. Schwarzer, G.; Carpenter, J.R.; Rücker, G. Fixed effect and random effects meta-analysis. In *Meta-Analysis with R*; Springer: Berlin/Heidelberg, Germany, 2015; pp. 21–53.
- 21. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* **1959**, 22, 719–748.
- 22. Thompson, S.G.; Turner, R.M.; Warn, D.E. Multilevel models for meta-analysis, and their application to absolute risk differences. *Stat. Methods Med. Res.* **2001**, *10*, 375–392. [CrossRef] [PubMed]
- 23. Paule, R.C.; Mandel, J. Consensus Values and Weighting Factors. J. Res. Natl. Bur. Stand. 1982, 87, 377–385. [CrossRef] [PubMed]
- 24. Harrer, M.; Cuijpers, P.; Furukawa, T.A.; Ebert, D.D. *Doing Meta-Analysis with R: A Hands-On Guide*, 1st ed.; Chapman & Hall/CRC Press: Boca Raton, FL, USA; London, UK, 2021.
- 25. IntHout, J.; Ioannidis, J.P.; Rovers, M.M.; Goeman, J.J. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open* **2016**, *6*, e010247. [CrossRef] [PubMed]
- Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, 366, 14898. [CrossRef] [PubMed]
- McGuinness, L.A.; Higgins, J.P.T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res. Synth. Methods* 2021, 12, 55–61. [CrossRef]
- 28. Tool, G.G.D. GRADEPro Guideline Development Tool. Available online: www.gradepro.org/ (accessed on 19 July 2022).
- 29. Ács, L.; Bányai, D.; Nemes, B.; Nagy, K.; Ács, N.; Bánhidy, F.; Rózsa, N. Maternal-related factors in the origin of isolated cleft palate-A population-based case-control study. *Orthod. Craniofac. Res.* **2020**, *23*, 174–180. [CrossRef]
- Acs, N.; Bánhidy, F.; Puhó, E.; Czeizel, A.E. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Res. Part A Clin. Mol. Teratol. 2005, 73, 989–996. [CrossRef]
- 31. Aro, T. Maternal diseases, alcohol consumption and smoking during pregnancy associated with reduction limb defects. *Early Hum. Dev.* **1983**, *9*, 49–57. [CrossRef]
- Botto, L.D.; Lynberg, M.C.; Erickson, J.D. Congenital heart defects, maternal febrile illness, and multivitamin use: A populationbased study. *Epidemiology* 2001, 12, 485–490. [CrossRef]
- Busby, A.; Dolk, H.; Armstrong, B. Eye anomalies: Seasonal variation and maternal viral infections. *Epidemiology* 2005, 16, 317–322. [CrossRef]
- Czeizel, A.E.; Puhó, E.H.; Acs, N.; Bánhidy, F. Use of specified critical periods of different congenital abnormalities instead of the first trimester concept. *Birth Defects Res. A Clin. Mol. Teratol.* 2008, 82, 139–146. [CrossRef]
- 35. Granroth, G. Defects of the central nervous system in Finland: III. Disease and drugs in pregnancy. *Early Hum. Dev.* **1978**, *2*, 147–162. [CrossRef]
- 36. Lynberg, M.C.; Khoury, M.J.; Lu, X.; Cocian, T. Maternal flu, fever, and the risk of neural tube defects: A population-based case-control study. *Am. J. Epidemiol.* **1994**, 140, 244–255. [CrossRef]
- 37. Ou, Y.; Mai, J.; Zhuang, J.; Liu, X.; Wu, Y.; Gao, X.; Nie, Z.; Qu, Y.; Chen, J.; Kielb, C.; et al. Risk factors of different congenital heart defects in Guangdong, China. *Pediatr. Res.* **2016**, *79*, 549–558. [CrossRef]
- Park, C.H.; Stewart, W.; Khoury, M.J.; Mulinare, J. Is there etiologic heterogeneity between upper and lower neural tube defects? *Am. J. Epidemiol.* 1993, 136, 1493–1501. [CrossRef]
- Saxén, I. Epidemiology of cleft lip and palate. An attempt to rule out chance correlations. Br. J. Prev. Soc. Med. 1975, 29, 103–110. [CrossRef]
- 40. Saxén, I. The association between maternal influenza, drug consumption and oral clefts. *Acta Odontol. Scand.* **1975**, *33*, 259–267. [CrossRef]
- 41. Dymanus, K.; Yu, J.; Carroll, W.; Lima, M.H.; Linder, D. The association of influenza on the incidence of orofacial clefts. *Cleft Palate-Craniofacial*. J. **2019**, 56, 61–62. [CrossRef]
- 42. Morens, D.M.; Daszak, P.; Markel, H.; Taubenberger, J.K. Pandemic COVID-19 Joins History's Pandemic Legion. *mBio* 2020, 11, e00812-20. [CrossRef]
- 43. Oster, M.E.; Riehle-Colarusso, T.; Alverson, C.J.; Correa, A. Associations between maternal fever and influenza and congenital heart defects. *J. Pediatr.* **2011**, *158*, 990–995. [CrossRef]
- Kurppa, K.; Holmberg, P.C.; Kuosma, E.; Aro, T.; Saxén, L. Anencephaly and maternal common cold. *Teratology* 1991, 44, 51–55. [CrossRef] [PubMed]
- 45. Medveczky, E.; Puhó, E.; Czeizel, A.E. An evaluation of maternal illnesses in the origin of neural-tube defects. *Arch. Gynecol. Obstet.* **2004**, 270, 244–251. [CrossRef] [PubMed]

- Shaw, G.M.; Todoroff, K.; Velie, E.M.; Lammer, E.J. Maternal illness, including fever and medication use as risk factors for neural tube defects. *Teratology* 1998, 57, 1–7. [CrossRef]
- 47. Kennedy, D.; Chitayat, D.; Winsor, E.J.; Silver, M.; Toi, A. Prenatally diagnosed neural tube defects: Ultrasound, chromosome, and autopsy or postnatal findings in 212 cases. *Am. J. Med. Genet.* **1998**, *77*, 317–321. [CrossRef]
- Avagliano, L.; Massa, V.; George, T.M.; Qureshy, S.; Bulfamante, G.P.; Finnell, R.H. Overview on neural tube defects: From development to physical characteristics. *Birth Defects Res.* 2019, 111, 1455–1467. [CrossRef]
- 49. Chitayat, D.; Matsui, D.; Amitai, Y.; Kennedy, D.; Vohra, S.; Rieder, M.; Koren, G. Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update. *J. Clin. Pharmacol.* **2016**, *56*, 170–175. [CrossRef]
- 50. Allam, E.; Windsor, L.; Stone, C. Cleft lip and palate: Etiology, epidemiology, preventive and intervention strategies. *Anat. Physiol.* **2014**, *4*, 3.
- 51. Mitchell, J.C.; Wood, R.J. Management of cleft lip and palate in primary care. J. Pediatr. Health Care 2000, 14, 13–19. [CrossRef]
- 52. Jones, M.C. Facial clefting. Etiology and developmental pathogenesis. Clin. Plast. Surg. 1993, 20, 599–606. [CrossRef]
- 53. Voigt, A.; Radlanski, R.J.; Sarioglu, N.; Schmidt, G. [Cleft lip and palate]. Pathologe 2017, 38, 241–247. [CrossRef]
- 54. Li, Z.; Ren, A.; Liu, J.; Pei, L.; Zhang, L.; Guo, Z.; Li, Z. Maternal flu or fever, medication use, and neural tube defects: A population-based case-control study in Northern China. *Birth Defects Res. Part A Clin. Mol. Teratol.* **2007**, *79*, 295–300. [CrossRef]
- 55. Hegyi, P.; Erőss, B.; Izbéki, F.; Párniczky, A.; Szentesi, A. Accelerating the translational medicine cycle: The Academia Europaea pilot. *Nat. Med.* **2021**, *27*, 1317–1319. [CrossRef]
- 56. Czeizel, A.E.; Acs, N.; Banhidy, F.; Puho, E.H.; Vogt, G. Primary prevention of congenital abnormalities due to high fever related maternal diseases by antifever therapy and folic acid supplementation. *Curr. Women's Health Rev.* 2007, *3*, 190–201. [CrossRef]